

Press release from the Annual General Meeting in Vimian Group AB (publ) on 22 May 2024

Vimian held its Annual General Meeting today 22 May 2024. The Annual General Meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting). The Annual General Meeting in Vimian Group AB (publ) resolved the following:

Approval of income statement and balance sheet for the financial year 2023 and discharge from liability

The Annual General Meeting approved the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet for the financial year 2023. All individuals who had served as board members or CEOs during 2023 were discharged from liability for the administration of the company in 2023.

Allocation of profit or loss

The Annual General Meeting resolved, in accordance with the board of directors' proposal, that the company's results shall be carried forward and that no dividends shall be paid to the shareholders.

Election of Board members, auditors, fees to the board of directors and auditors

The Annual General Meeting resolved, in accordance with the nomination committee's proposal, that the number of Board members shall be six, equivalent to a net reduction of one board member, without deputy members, and that the company shall have one auditor without deputy auditors.

In accordance with the nomination committee's proposal, Robert Belkic, Theodor Bonnier, Gabriel Fitzgerald, Petra Rumpf and Frida Westerberg were re-elected, and Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board. The accounting firm Grant Thornton Sweden AB was re-elected as auditor, and it was noted that the authorised public accountant Carl-Johan Regell will continue to be auditor in charge.

The Annual General Meeting further resolved, in accordance with the nomination committee's proposal, that the fees to the Board shall be EUR 225,000 in total for the period until the end of the next Annual General Meeting, to be allocated with EUR 75,000 to the chairman of the Board of Directors and EUR 50,000 to each of the other members elected by the Annual General Meeting, with the exception of Gabriel Fitzgerald and Theodor Bonnier who have announced that they refrain from fees. The Annual General Meeting further resolved that, in accordance with the nomination committee's proposal, auditor fees shall be paid in accordance with approved invoice.

Authorisation to issue new shares

The Annual General Meeting resolved to, in accordance with the Board's proposal, authorise the Board, on one or several occasions, and with or without pre-emptive rights for shareholders, to resolve on the issue of new shares, comprising a total of not more than 20 per cent of the total number of outstanding shares in the company after the utilization of the authorisation. Such share issue resolution may be made with or without provisions for contribution in kind, set-off or other conditions.

Long-term incentive program 2024 (LTI 2024) in the form of employee stock options

The Annual General Meeting resolved, in accordance with the board of directors' proposal, to adopt a long-term incentive program (LTI 2024) for employees in Vimian, including not more than 160 persons, in the form of employee stock options. Within the framework of the program, it was also resolved to issue and transfer not more than 6,500,000 warrants.

For further information, please contact:

Maria Dahllöf Tullberg

Head of IR, Communications & Sustainability

maria.tullberg@vimian.com

+46 736 26 88 86

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 80 markets, has 1,100 employees and annual revenues of approximately EUR 330 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company's Certified Adviser.

Attachments

[Press release from the Annual General Meeting in Vimian Group AB \(publ\) on 22 May 2024](#)